Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoping Xu

Showing results (401-410 of 413) with videos related to

Pageof 42
Sort By:
BMC Biology|September 1, 2016
The pesticidal Cry6Aa toxin from Bacillus thuringiensis is structurally similar to HlyE-family alpha pore-forming toxinsAlexey Dementiev, Jason Board, Anand Sitaram, et al.
Oncogene|November 25, 2025
Prevention of cancer initiation by augmenting MHC-I antigen presentation via EZH2 inhibitionWei Ding, Zihan Ding, Qinghong Zeng, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 19, 2020
Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived CardiomyocytesUmber Saleem, Berend J van Meer, Puspita A Katili, et al.
Ebiomedicine|October 2, 2015
Associations between proteasomal activator PA28γ and outcome of oral squamous cell carcinoma: Evidence from cohort studies and functional analysesJing Li, Xiaodong Feng, Chongkun Sun, et al.
Respiratory Research|September 22, 2020
The effect of vascular risk factor burden on the severity of COVID-19 illness, a retrospective cohort studyHouwei Du, Xiaobin Pan, Nan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
Improving the developability profile of pyrrolidine progesterone receptor partial agonistsLara S Kallander, David G Washburn, Tram H Hoang, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2013
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophoreDavid G Washburn, Dennis A Holt, Jason Dodson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2Robert N Willette, Weike Bao, Sandhya Nerurkar, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part IKevin S Thorneloe, Anthony C Sulpizio, Zuojun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Pageof 42

Showing results (401-410 of 413) with videos related to

Sort By:
Pageof 42
BMC Biology|September 1, 2016
The pesticidal Cry6Aa toxin from Bacillus thuringiensis is structurally similar to HlyE-family alpha pore-forming toxinsAlexey Dementiev, Jason Board, Anand Sitaram, et al.
Oncogene|November 25, 2025
Prevention of cancer initiation by augmenting MHC-I antigen presentation via EZH2 inhibitionWei Ding, Zihan Ding, Qinghong Zeng, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 19, 2020
Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived CardiomyocytesUmber Saleem, Berend J van Meer, Puspita A Katili, et al.
Ebiomedicine|October 2, 2015
Associations between proteasomal activator PA28γ and outcome of oral squamous cell carcinoma: Evidence from cohort studies and functional analysesJing Li, Xiaodong Feng, Chongkun Sun, et al.
Respiratory Research|September 22, 2020
The effect of vascular risk factor burden on the severity of COVID-19 illness, a retrospective cohort studyHouwei Du, Xiaobin Pan, Nan Liu, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2009
Improving the developability profile of pyrrolidine progesterone receptor partial agonistsLara S Kallander, David G Washburn, Tram H Hoang, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2013
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophoreDavid G Washburn, Dennis A Holt, Jason Dodson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2Robert N Willette, Weike Bao, Sandhya Nerurkar, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2008
N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part IKevin S Thorneloe, Anthony C Sulpizio, Zuojun Lin, et al.
Bioorganic & Medicinal Chemistry Letters|May 27, 2008
Development of potent and selective small-molecule human Urotensin-II antagonistsJohn J McAtee, Jason W Dodson, Sarah E Dowdell, et al.
Pageof 42